EquitiesIndia.com

Healthcare · Biotechnology

Onesource Specialty Pharma Ltd.

ONESOURCE

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

NSE: ONESOURCEOfficial website ↗

Key metrics

Market Cap

₹16,496 cr

P/E Ratio

831.73x

P/B Ratio

2.81x

ROE

-0.31%

ROCE

1.28%

Debt / Equity

0.16x

Net Margin

-1.24%

Dividend Yield

EPS

₹-1.63

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 38.63%FII: 26.67%Public: 34.70%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Onesource Specialty Pharma Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.